![Kim D. Janda](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kim D. Janda
Directeur/Membre du Conseil chez SORRENTO THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Postes actifs de Kim D. Janda
Sociétés | Poste | Début | Fin |
---|---|---|---|
SORRENTO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/04/2012 | - |
Independent Dir/Board Member | 01/04/2012 | - | |
The Scripps Research Institute
![]() The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | 01/01/1996 | - |
Worm Institute For Research & Medicine | Directeur/Membre du Conseil | 01/01/2005 | - |
Cessation Therapeutics, LLC
![]() Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Kim D. Janda
Anciens postes connus de Kim D. Janda
Sociétés | Poste | Début | Fin |
---|---|---|---|
Drug Abuse Sciences | Fondateur | - | - |
CombiChem, Inc.
![]() CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Fondateur | - | - |
Formation de Kim D. Janda
University of South Florida | Undergraduate Degree |
University of Arizona | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Opérationnelle
Director/Board Member | 3 |
Founder | 2 |
Independent Dir/Board Member | 1 |
Sectorielle
Consumer Services | 5 |
Health Technology | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SORRENTO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
CombiChem, Inc.
![]() CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Commercial Services |
Drug Abuse Sciences | |
Cessation Therapeutics, LLC
![]() Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Health Technology |
- Bourse
- Insiders
- Kim D. Janda
- Expérience